Literature DB >> 11889444

Temporary auxiliary liver transplantation from a living donor to an adult recipient with familial amyloid polyneuropathy.

Toshihiko Ikegami1, Seiji Kawasaki, Yasunari Ohno, Hisanao Chisuwa, Koichi Urata, Yuichi Nakazawa, Yasuhiko Hashikura, Masaru Terada, Shinichi Miyagawa, Yo-ichi Takei Yi, Takahiko Tokuda, Shu-ichi Ikeda Si.   

Abstract

A 33-year-old patient with familial amyloid polyneuropathy (FAP) underwent temporary auxiliary partial orthotopic liver transplantation (APOLT) from a living donor with a small-for-size graft. The auxiliary left lobar graft, which weighed only 230 g, was orthotopically transplanted after resection of the recipient's left lobe. The right portal vein was transected to induce compensatory hypertrophy of the left lobar graft. Posttransplant computed tomography showed atrophy of the native liver and hypertrophy of the graft, the volume of which had increased to 446 ml by postoperative day 41. The remnant native liver was removed 6 weeks after APOLT, and there were no signs of liver dysfunction during the postoperative course. Our experience with this case suggests that temporary APOLT is the treatment of choice, guaranteeing a sufficient margin of safety for both donor and recipient, in living donor liver transplants for FAP where the donor's left lobe is disproportionately small.

Entities:  

Mesh:

Year:  2002        PMID: 11889444     DOI: 10.1097/00007890-200202270-00027

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

Review 1.  Hepatofugal portal flow associated with acute rejection in living-donor auxiliary partial orthotopic liver transplantation: a report of one case and literature review.

Authors:  Lai Wei; Zhishui Chen; Xiaoping Chen; Dunfeng Du; Kaiyan Li; Jipin Jiang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

2.  Living donor liver transplantation: issues regarding left liver grafts.

Authors:  Y Hashikura; S Kawasaki
Journal:  HPB (Oxford)       Date:  2004       Impact factor: 3.647

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.